Phase 2, Double-Blind Randomized, 3-way Cross-Over Liquid Meal Study With Optimal Doses of SC Administered Insulin Lispro With and Without rHuPH20 and Regular Human Insulin With rHuPH20 to Compare Pharmacokinetics, Postprandial Glycemic Response, and Optimal Insulin Dose in Patients With T2DM.
Phase of Trial: Phase II
Latest Information Update: 28 Jun 2010
At a glance
- Drugs Hyaluronidase; Insulin; Insulin lispro
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Sponsors Halozyme Therapeutics
- 28 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrails.gov.
- 28 Jun 2010 Acutal patient number (n=23) as reported by ClinicalTrials.gov.
- 07 May 2010 Results will be presented at the President's Poster Session at the American Diabetes Association (ADA) 70th Scientific Sessions, as reported by Halozyme Therapeutics.